医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

BRUKINSA

BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

バイオテクノロジーヘルスケアヘルス一般感染症腫瘍学臨床試験製薬　 TimeLine: BeiGene Announces BRUKINSA Markets zanubrutinib

2022年06月13日

IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia

IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BRUKINSA Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia IRC Determines zanubrutinib

2022年04月11日

BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: BRUKINSA for the Treatment of Waldenström s Macroglobulinemia zanubrutinib

2022年03月15日

$BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma$

BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: BeiGene Announces Health Canada Approval for BRUKINSA in Relapsed or Refractory Marginal Zone Lymphoma zanubrutinib

2022年03月03日

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

ヘルスケア腫瘍学製薬　 TimeLine: BeiGene Announces BRUKINSA FDA Acceptance of Supplemental New Drug in Chronic Lymphocytic Leukemia zanubrutinib

2022年02月22日

BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma

BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma zanubrutinib

2022年02月22日

BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia

BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia

その他ヘルスバイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: BeiGene Announces Approval for BRUKINSA by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia zanubrutinib

2022年02月17日

BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation

BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Announces Acceptance of Supplemental New Drug BRUKINSA in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation zanubrutinib

2022年01月28日

BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia

BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BRUKINSA in Waldenström’s Macroglobulinemia zanubrutinib

2022年01月20日

BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for Pamiparib

BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for Pamiparib

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: BeiGene Announces Inclusion in the China National Reimbursement Drug List BRUKINSA NRDL zanubrutinib

2021年12月03日